<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Phys Ther Sci</journal-id><journal-id journal-id-type="iso-abbrev">J Phys Ther Sci</journal-id><journal-id journal-id-type="publisher-id">JPTS</journal-id><journal-title-group><journal-title>Journal of Physical Therapy Science</journal-title></journal-title-group><issn pub-type="ppub">0915-5287</issn><issn pub-type="epub">2187-5626</issn><publisher><publisher-name>The Society of Physical Therapy Science</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25013273</article-id><article-id pub-id-type="pmc">4085198</article-id><article-id pub-id-type="publisher-id">jpts-2013-473</article-id><article-id pub-id-type="doi">10.1589/jpts.26.813</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original</subject></subj-group></article-categories><title-group><article-title>Eltgol Acutelly Improves Airway Clearance and Reduces Static Pulmonary
Volumes in Adult Cystic Fibrosis Patients</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Guimar&#x000e3;es</surname><given-names>Fernando Silva</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref rid="cor1" ref-type="corresp"><sup>*</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lopes</surname><given-names>Agnaldo Jos&#x000e9;</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mo&#x000e7;o</surname><given-names>Vanessa Joaquim Ribeiro</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Cavalcanti de Souza</surname><given-names>Felipe</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Silveira de Menezes</surname><given-names>Sara L&#x000fa;cia</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><aff id="aff1"><label>1)</label> Rehabilitation Science Graduate Program, Augusto Motta
University Centre (UNISUAM),
Brazil</aff><aff id="aff2"><label>2)</label> Physical Therapy Department, Federal University of Rio de
Janeiro, Brazil</aff><aff id="aff3"><label>3)</label> Laboratory of Respiratory Physiology, University of the
State of Rio de Janeiro, Brazil</aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>Corresponding author. Fernando Silva Guimar&#x000e3;es, Rehabilitation Science Graduate Program, Augusto Motta
University Centre (UNISUAM): Pra&#x000e7;a das Na&#x000e7;&#x000f5;es, 34, Bonsucesso, Rio de Janeiro 21041-021,
Brazil. (E-mail:
<email xlink:href="fguimaraes_pg@yahoo.com.br">fguimaraes_pg@yahoo.com.br</email>)</corresp></author-notes><pub-date pub-type="epub"><day>30</day><month>6</month><year>2014</year></pub-date><pub-date pub-type="ppub"><month>6</month><year>2014</year></pub-date><volume>26</volume><issue>6</issue><fpage>813</fpage><lpage>816</lpage><history><date date-type="received"><day>15</day><month>10</month><year>2013</year></date><date date-type="accepted"><day>07</day><month>1</month><year>2014</year></date></history><permissions><copyright-statement>2014&#x000a9;by the Society of Physical Therapy Science</copyright-statement><copyright-year>2014</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/"><license-p>This is an open-access article distributed under the terms of the Creative
Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License. </license-p></license></permissions><abstract><p> Chest physical therapy techniques are essential in order to reduce the frequency of
recurrent pulmonary infections that progressively affect lung function in cystic fibrosis
patients. Recently, ELTGOL (L&#x02019;Expiration Lente Totale Glotte Ouverte en d&#x000e9;cubitus Lat&#x000e9;ral)
emerged as an inexpensive and easy to perform therapeutic option. The aim of this study
was to compare the acute effects of ELTGOL and the Flutter valve in stable adult patients
with cystic fibrosis. [Subjects and Methods] This was a randomized, crossover study with a
sample of cystic fibrosis outpatients. The subjects underwent two protocols (Flutter Valve
and ELTGOL interventions, referred to as ELTGOL and FLUTTER) in a randomized order with a
one-week washout interval between them. The main outcomes were pulmonary function
variables and expectorated sputum dry weight. [Results] ELTGOL cleared 0.34&#x02005;g more of
secretions than FLUTTER (95% CI 0.11 to 0.57). When comparing the physiological effects of
ELTGOL and FLUTTER, the first was superior in improving airway resistance (&#x02212;0.51
cmH<sub>2</sub>O/L/s; 95% CI &#x02212;0.88 to &#x02212;0.14) and airway conductance (0.016
L/s/cmH<sub>2</sub>O; 95% CI 0.008 to 0.023). [Conclusion] ELTGOL promoted higher
secretion removal and improvement in airway resistance and conductance than the Flutter
valve. These techniques were equivalent in reducing the pulmonary hyperinflation and air
trapping in cystic fibrosis patients.</p></abstract><kwd-group><title>Key words</title><kwd>Chest physiotherapy</kwd><kwd>Cystic fibrosis</kwd><kwd>ELTGOL</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>INTRODUCTION</title><p>A few years ago, cystic fibrosis was considered a childhood disease, but life expectancy
has increased in recent years due to medical advances and greater understanding of its
pathophysiology, bringing the average age to 36.9&#x02005;years old<xref rid="r1" ref-type="bibr">1</xref><sup>)</sup>. In this context, chest physical therapy (CPT) has been playing an
important role, aiding mucociliary clearance, which directly influences the survival and
prognosis of these patients<xref rid="r2" ref-type="bibr">2</xref>, <xref rid="r3" ref-type="bibr">3</xref><sup>)</sup>.</p><p>In the last few years, a number of CPT techniques have been proposed in order to reduce the
frequency of recurrent pulmonary infections that progressively affect lung function<xref rid="r4" ref-type="bibr">4</xref><sup>)</sup>, but many of these procedures require daily
professional assistance, resulting in poor adherence to treatment. For this reason,
techniques that allow independent treatment were developed and have been studied, such as
autogenic drainage, active cycle of breathing, oral oscillatory devices, high-frequency
chest oscillation, positive expiratory pressure, and intrapulmonary percussive
ventilation<xref rid="r5" ref-type="bibr">5</xref><sup>)</sup>. Flutter valve<sup>&#x000ae;</sup>
(Varioraw SARL, Scandipharm Inc, Birmingham, AL, USA), which combines positive expiratory
pressure with high-frequency oscillations within airways, is a well-recognized and widely
used device for the treatment of patients with cystic fibrosis<xref rid="r6" ref-type="bibr">6</xref><sup>)</sup>. In the last few years, ELTGOL (L&#x02019;Expiration Lente Totale Glotte
Ouverte en d&#x000e9;cubitus Lat&#x000e9;ral)<xref rid="r7" ref-type="bibr">7</xref><sup>)</sup> has emerged
as an inexpensive and easy to perform therapeutic option. During ELTGOL, the patient lies
laterally, with the affected lung in the dependent position, while performing a series of
slow expirations with the glottis open. According to its original description, this
technique is indicated for hypersecretive, cooperative patients, and those in which the
forced maneuvers pose a higher risk of causing harmful airway collapses<xref rid="r8" ref-type="bibr">8</xref><sup>)</sup>. Therefore, as there are very few studies about the
physiological and clinical effects of ELTGOL, the aim of this study was to compare the acute
effects of ELTGOL and the Flutter valve in stable adult patients with cystic fibrosis.</p></sec><sec sec-type="methods" id="s2"><title>SUBJECTS AND METHODS</title><p>This was a randomized, crossover study with a convenience sample of cystic fibrosis
outpatients. The patients underwent two protocols (Flutter Valve and ELTGOL interventions),
in a randomized order with a one-week washout interval between them. After the washout
period and prior to the second intervention, the patients were reexamined by a physician to
ensure that they remained stable. Pulmonary function tests were performed at the Pulmonary
Function Laboratory (University of Rio de Janeiro), and the interventions were conducted by
a cardiopulmonary physical therapist, always at the same time of the day, with the sessions
scheduled between 9:00 and 12:00 AM. The allocation sequence was computer generated using
one random block with a block size of fourteen. The protocol to be applied was revealed to
the investigator only at the onset of each experimental sequence, and the participants were
oriented to maintain their regular treatments during the period of the study.</p><p>We included individuals with clinical and laboratory (sweat test and/or deoxyribonucleic
acid &#x02212; DNA mutation analysis) diagnoses of CF from the Pneumology Service of Pedro Ernesto
University Hospital (State University of Rio de Janeiro). Patients under any
physiotherapeutic treatment and those with acute chest pain, recent history of hemoptysis,
pneumothorax at least one year before the study, respiratory infection in the four weeks
preceding the study, or a confirmed diagnosis of asthma were not included. According to the
Helsinki Declaration, our Institutional Ethics Committee approved the study, and all
subjects signed an informed consent form.</p><p>Sample size was estimated using the SigmaStat 3.1 software (SYSTAT Software Inc., Point
Richmond, CA, USA), considering a power of 80% and &#x003b1; = 5%. According to the data from
Konstan et al<xref rid="r9" ref-type="bibr">9</xref><sup>)</sup>, 8 subjects were required
for the study in order to detect a 74% difference and a 64% standard deviation in the
secretion production (main outcome).</p><p>Two days before the testing protocols, each subject visited the laboratory for an
introductory session to become familiar with the equipment and the procedures. Both
interventions were preceded by the inhalation of two puffs of 100 mcg of salbutamol,
followed by a series of five minutes of coughing. The Flutter intervention (FLUTTER) was
performed with the patients comfortably seated and breathing through the device for 15
minutes, starting off from total pulmonary capacity<xref rid="r9" ref-type="bibr">9</xref><sup>)</sup>. The device position (angle) was determined by the patient (within a
limit of 30&#x000b0;) according to his/her adaptation and perception of the effectiveness of sputum
clearance<xref rid="r10" ref-type="bibr">10</xref><sup>)</sup>. In the ELTGOL intervention
(ELTGOL), the subjects were in the side-lying position and performed slow exhalations
through a mouthpiece, from the functional residual capacity (FRC) to the residual volume
(RV). They performed three sets of ten repetitions with a two-minute interval between them,
for both right and left lateral decubitus. During ELTGOL and FLUTTER, the patients were free
to cough, and after both interventions, a 5-min session of coughing ensued.</p><p>The foremost outcome with respect to airway clearance was the expectorated sputum dry
weight. Expectorated sputum was collected during the interventions and the subsequent
coughing series using a sputum trap. The dry weight was determined after the samples had
been in a drying oven at 65&#x000b0;C for 3 days to ensure complete dryness<xref rid="r11" ref-type="bibr">11</xref><sup>)</sup>.</p><p>Forced spirometry, body plethysmography, and diffusion capacity were used to evaluate the
short-term physiological effects of interventions (Collins Plus Pulmonary Function Testing
Systems, Warren E. Collins, Inc., Braintree, MA, USA). These tests followed ATS/ERS
standards<xref rid="r12" ref-type="bibr">12</xref><sup>)</sup>, and predicted values were
set according to the equations for the Brazilian population<xref rid="r13" ref-type="bibr">13</xref>, <xref rid="r14" ref-type="bibr">14</xref><sup>)</sup>. The variables forced
vital capacity (FVC), forced expiratory volume at the first second (FEV<sub>1</sub>),
FVC/FEV<sub>1</sub>, inspiratory capacity (IC), total lung capacity (TLC), residual volume
(RV), airway resistance (Raw), and specific conductance (Gaw) were recorded after the first
and second 5-min coughing series.</p><p>The data were analyzed using the software SigmaStat 3.1 software (SYSTAT Software Inc.,
Point Richmond, CA, USA). The between-interventions comparison was performed according to
the pre- and post-intervention difference for each physiological variable (95% CI).
According to the data distribution, the paired t-test or Mann-Whitney rank sum test were
used to compare pre- and post-intervention values within the same intervention. Differences
were considered significant when p&#x0003c;0.05.</p></sec><sec sec-type="results" id="s3"><title>RESULTS</title><p>The data from the fourteen patients were collected between February 2011 and December 2011.
All enrolled subjects completed the study and tolerated well the experimental protocol.
<xref rid="tbl_001" ref-type="table">Table 1</xref><table-wrap id="tbl_001" orientation="portrait" position="float"><label>Table 1.</label><caption><title> Functional and demographic characteristics of the adult patients with cystic
fibrosis (n=14)</title></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Age (yrs)</td><td align="center" valign="top" rowspan="1" colspan="1">26.7 &#x000b1; 5.4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Gender (M/F)</td><td align="center" valign="top" rowspan="1" colspan="1">7/7 </td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Weight (kg)</td><td align="center" valign="top" rowspan="1" colspan="1">53.2 &#x000b1; 11.7</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Height (m)</td><td align="center" valign="top" rowspan="1" colspan="1">1.63 &#x000b1; 0.08</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="center" valign="top" rowspan="1" colspan="1">19.7 &#x000b1; 2.7</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FEV<sub>1</sub> (% pred)</td><td align="center" valign="top" rowspan="1" colspan="1">33.9 &#x000b1; 13.8</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FVC (% pred)</td><td align="center" valign="top" rowspan="1" colspan="1">52.7 &#x000b1; 20.2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FEV<sub>1</sub>/FVC (%)</td><td align="center" valign="top" rowspan="1" colspan="1">54.9 &#x000b1; 6.4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FEF<sub>25&#x02013;75%</sub> (% pred)</td><td align="center" valign="top" rowspan="1" colspan="1">12.1 &#x000b1; 6.2</td></tr></tbody></table><table-wrap-foot><p>FEV<sub>1</sub> = forced expiratory volume in 1 second; FVC = forced vital capacity;
FEF<sub>25&#x02013;75</sub> = forced expiratory flow between 25% and 75% of the forced vital
capacity; BMI = body mass index</p></table-wrap-foot></table-wrap> shows the anthropometric and functional baseline characteristics of the
participants. There were neither differences between pre-intervention values nor order
effects. Mean (SD) scores, mean (SD) differences within interventions, and mean (SD)
differences between interventions for sputum dry weight and the physiological measurements
are shown in <xref rid="tbl_002" ref-type="table">Table 2</xref><table-wrap id="tbl_002" orientation="portrait" position="float"><label>Table 2.</label><caption><title> Sputum production and pulmonary function tests results in the FLUTTER and ELTGOL
interventions</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" rowspan="3" colspan="1"/><th align="center" valign="middle" colspan="2" rowspan="1">Pre-test</th><th align="center" valign="middle" colspan="2" rowspan="1">Post-test</th><th align="center" valign="middle" colspan="2" rowspan="1">Post-test minus pre-test</th><th align="center" valign="middle" rowspan="1" colspan="1">Difference between<break/>interventions</th></tr><tr><th colspan="7" rowspan="1"><hr/></th></tr><tr><th align="center" valign="top" rowspan="1" colspan="1">Flutter</th><th align="center" valign="top" rowspan="1" colspan="1">ELTGOL</th><th align="center" valign="top" rowspan="1" colspan="1">Flutter</th><th align="center" valign="top" rowspan="1" colspan="1">ELTGOL</th><th align="center" valign="top" rowspan="1" colspan="1">Flutter</th><th align="center" valign="top" rowspan="1" colspan="1">ELTGOL</th><th align="center" valign="top" rowspan="1" colspan="1">ELTGOL minus Flutter</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Sputum Clearance</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="2" style="padding-left:15pt" rowspan="1">Sputum dry weight (g)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.52 (0.59)</td><td align="center" rowspan="1" colspan="1">0.86 (0.65)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.34 (0.11 to 0.57)</td></tr><tr><td colspan="8" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Spirometry</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15pt" rowspan="1" colspan="1">FEV<sub>1</sub> (L)</td><td align="center" rowspan="1" colspan="1">1.17 (0.53)</td><td align="center" rowspan="1" colspan="1">1.09 (0.51)</td><td align="center" rowspan="1" colspan="1">1.17 (0.51)</td><td align="center" rowspan="1" colspan="1">1.11 (0.50)</td><td align="center" rowspan="1" colspan="1">0.01 (0.06)</td><td align="center" rowspan="1" colspan="1">0.02 (0.14)</td><td align="center" rowspan="1" colspan="1">0.01 (&#x02212;0.59 to 0.08)</td></tr><tr><td align="left" style="padding-left:15pt" rowspan="1" colspan="1">FVC (L)</td><td align="center" rowspan="1" colspan="1">2.13 (0.91)</td><td align="center" rowspan="1" colspan="1">2.02 (0.91)</td><td align="center" rowspan="1" colspan="1">2.17 (0.83)</td><td align="center" rowspan="1" colspan="1">2.10 (0.90)</td><td align="center" rowspan="1" colspan="1">0.03 (0.15)</td><td align="center" rowspan="1" colspan="1">0.08 (0.18)</td><td align="center" rowspan="1" colspan="1">0.05 (&#x02212;0.06 to 0.17)</td></tr><tr><td align="left" style="padding-left:15pt" rowspan="1" colspan="1">FEV<sub>1</sub>/FVC (%)</td><td align="center" rowspan="1" colspan="1">54.9 (6.4)</td><td align="center" rowspan="1" colspan="1">54.9 (7.1)</td><td align="center" rowspan="1" colspan="1">54.0 (8.07)</td><td align="center" rowspan="1" colspan="1">53.29 (7.82)</td><td align="center" rowspan="1" colspan="1">&#x02212;0.93 (3.54)</td><td align="center" rowspan="1" colspan="1">&#x02212;1.64 (5.24)</td><td align="center" rowspan="1" colspan="1">&#x02212;0.71 (&#x02212;4.08 to 2.66)</td></tr><tr><td align="left" style="padding-left:15pt" rowspan="1" colspan="1">FEF<sub>25&#x02013;75 </sub>(L)</td><td align="center" rowspan="1" colspan="1">0.47 (0.26)</td><td align="center" rowspan="1" colspan="1">0.44 (0.27)</td><td align="center" rowspan="1" colspan="1">0.57 (0.45)</td><td align="center" rowspan="1" colspan="1">0.48 (0.31)</td><td align="center" rowspan="1" colspan="1">0.10 (0.32)</td><td align="center" rowspan="1" colspan="1">0.04 (0.21)</td><td align="center" rowspan="1" colspan="1">&#x02212;0.06 (&#x02212;0.31 to 0.19)</td></tr><tr><td colspan="8" rowspan="1"><hr/></td></tr><tr><td align="center" rowspan="1" colspan="1">Plethysmography</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15pt" rowspan="1" colspan="1">IC (L)</td><td align="center" rowspan="1" colspan="1">1.52 (0.56)</td><td align="center" rowspan="1" colspan="1">1.50 (0.68)</td><td align="center" rowspan="1" colspan="1">1.54 (0.65)</td><td align="center" rowspan="1" colspan="1">1.54 (0.71)</td><td align="center" rowspan="1" colspan="1">0.02 (0.26)</td><td align="center" rowspan="1" colspan="1">0.04 (0.19)</td><td align="center" rowspan="1" colspan="1">0.02 (&#x02212;0.17 to 0.20)</td></tr><tr><td align="left" style="padding-left:15pt" rowspan="1" colspan="1">VC (L)</td><td align="center" rowspan="1" colspan="1">2.01 (0.84)</td><td align="center" rowspan="1" colspan="1">2.00 (0.87)</td><td align="center" rowspan="1" colspan="1">2.02 (0.78)</td><td align="center" rowspan="1" colspan="1">2.01 (0.92)</td><td align="center" rowspan="1" colspan="1">0.02 (0.20)</td><td align="center" rowspan="1" colspan="1">0.01 (0.15)</td><td align="center" rowspan="1" colspan="1">&#x02212;0.1 (&#x02212;0.40 to 0.33)</td></tr><tr><td align="left" style="padding-left:15pt" rowspan="1" colspan="1">TLC (L)</td><td align="center" rowspan="1" colspan="1">5.86 (1.74)</td><td align="center" rowspan="1" colspan="1">5.71 (1.92)</td><td align="center" rowspan="1" colspan="1">5.22 (1.79)</td><td align="center" rowspan="1" colspan="1">5.27 (1.42)</td><td align="center" rowspan="1" colspan="1">&#x02212;0.64 (0.93)</td><td align="center" rowspan="1" colspan="1">&#x02212;0.44 (1.22)</td><td align="center" rowspan="1" colspan="1">0.19 (&#x02212;0.30 to 0.69)</td></tr><tr><td align="left" style="padding-left:15pt" rowspan="1" colspan="1">FRC (L)</td><td align="center" rowspan="1" colspan="1">4.33 (1.36)</td><td align="center" rowspan="1" colspan="1">4.21 (1.62)</td><td align="center" rowspan="1" colspan="1">3.70 (1.47)</td><td align="center" rowspan="1" colspan="1">3.74 (1.10)</td><td align="center" rowspan="1" colspan="1">&#x02212;0.63 (1.01)</td><td align="center" rowspan="1" colspan="1">&#x02212;0.48 (1.22)</td><td align="center" rowspan="1" colspan="1">0.15 (&#x02212;0.41 to 0.72)</td></tr><tr><td align="left" style="padding-left:15pt" rowspan="1" colspan="1">RV (L)</td><td align="center" rowspan="1" colspan="1">3.84 (1.29)</td><td align="center" rowspan="1" colspan="1">3.71 (1.73)</td><td align="center" rowspan="1" colspan="1">3.21 (1.36)</td><td align="center" rowspan="1" colspan="1">3.26 (1.05)</td><td align="center" rowspan="1" colspan="1">&#x02212;0.63 (0.95)</td><td align="center" rowspan="1" colspan="1">&#x02212;0.45 (1.20)</td><td align="center" rowspan="1" colspan="1">0.18 (&#x02212;0.37 to 0.73)</td></tr><tr><td align="left" style="padding-left:15pt" rowspan="1" colspan="1">RV/TLC (%)</td><td align="center" rowspan="1" colspan="1">65.21 (9.05)</td><td align="center" rowspan="1" colspan="1">64.43 (9.75)</td><td align="center" rowspan="1" colspan="1">60.43 (9.42)</td><td align="center" rowspan="1" colspan="1">61.79 (12.15)</td><td align="center" rowspan="1" colspan="1">&#x02212;4.79 (7.04)</td><td align="center" rowspan="1" colspan="1">&#x02212;2.64 (6.32)</td><td align="center" rowspan="1" colspan="1">2.15 (&#x02212;1.78 to 6.07)</td></tr><tr><td align="left" style="padding-left:15pt" rowspan="1" colspan="1">Raw (cmH<sub>2</sub>O/L/s)</td><td align="center" rowspan="1" colspan="1">4.35 (1.06)</td><td align="center" rowspan="1" colspan="1">4.58 (1.22)</td><td align="center" rowspan="1" colspan="1">3.49 (1.05)</td><td align="center" rowspan="1" colspan="1">3.21 (1.14)</td><td align="center" rowspan="1" colspan="1">&#x02212;0.86 (0.65)</td><td align="center" rowspan="1" colspan="1">&#x02212;1.37 (0.92)</td><td align="center" rowspan="1" colspan="1">&#x02212;0.51 (&#x02212;0.88 to &#x02212;0.14)</td></tr><tr><td align="left" style="padding-left:15pt" rowspan="1" colspan="1">SGVa (L/s/cmH<sub>2</sub>O)</td><td align="center" rowspan="1" colspan="1">0.053 (0.02)</td><td align="center" rowspan="1" colspan="1">0.053 (0.02)</td><td align="center" rowspan="1" colspan="1">0.062 (0.02)</td><td align="center" rowspan="1" colspan="1">0.078 (0.025)</td><td align="center" rowspan="1" colspan="1">0.009 (0.008)</td><td align="center" rowspan="1" colspan="1">0.025 (0.016)</td><td align="center" rowspan="1" colspan="1">0.016 (0.008 to 0.023)</td></tr></tbody></table><table-wrap-foot><p>Values are means (SD or CI 95%). FEV<sub>1</sub> = forced expiratory volume in 1
second; FVC = forced vital capacity; FEF<sub>25&#x02013;75</sub> = forced expiratory flow
between 25 and 75% of the FVC; IC = inspiratory capacity; VC = vital capacity; TLC =
total lung capacity; FRC = functional residual capacity; RV = residual volume; Raw =
airway resistance; SGVa = airway conductance</p></table-wrap-foot></table-wrap>. ELTGOL cleared 0.34&#x02005;g more of secretions than FLUTTER (95% CI 0.11 to 0.57; p
= 0.024). In the within-intervention analysis, FLUTTER reduced TLC (p = 0.024), FRC (p =
0.035), RV (p = 0.027), RV/TLC (p = 0.024), Raw (p &#x0003c; 0.001), and increased airways
conductance (SGVa; p = 0.001) and the peripheral arterial oxygenation (SpO<sub>2</sub>; p =
0.017). In ELTGOL, there was a reduction in Raw (p &#x0003c; 0.001) and improvement in SGVa (p
&#x0003c; 0.001) and SpO<sub>2</sub> (p = 0.034). When comparing the physiological effects of
ELTGOL and FLUTTER, the former was superior in improving Raw (&#x02212;0.51 cmH<sub>2</sub>O/L/s;
95% CI &#x02212;0.88 to &#x02212;0.14) and SGVa (0.016 L/s/cmH<sub>2</sub>O; 95% CI 0.008 to 0.023; p =
0.003).</p></sec><sec sec-type="discussion" id="s4"><title>DISCUSSION</title><p>In this study, sputum production and the physiological consequences of two airway clearance
techniques in adult cystic fibrosis patients were evaluated. We opted to compare ELTGOL with
the Flutter valve because the latter is a well-established and widely used technique for the
treatment of cystic fibrosis patients<xref rid="r6" ref-type="bibr">6</xref><sup>)</sup>.
Both techniques resulted in physiological benefits, but ELTGOL promoted higher secretion
removal and improvement in airway resistance and conductance than the Flutter valve.
Although only the Flutter valve reduced pulmonary hyperinflation, a clinically relevant
difference between the two evaluated techniques was not found for CPT, RV, and RV/CPT in
this study, as shown by the confidence interval analysis.</p><p>Although airway clearance techniques are widely used, their physiological mechanisms and
consequences are still poor understood. Airway clearance techniques are intended to remove
pulmonary secretions from the periphery to more central airways, which can take several
minutes after the end of their application. In our study, because we evaluated only the
immediate effects of two chest physiotherapy techniques, it is likely that a significant
amount of mucus was still in intermediate airways at the second pulmonary function
evaluation. The low sensitivity of forced spirometry to detect changes in the lung periphery
and the presence of secretions in the intermediate and central airways after the
interventions may explain the absence of significant differences in spirometric variables
observed in our study<xref rid="r15" ref-type="bibr">15</xref><sup>)</sup>. Conversely, by
means of impulse oscillometry, Scheidt et al. (2010)<xref rid="r16" ref-type="bibr">16</xref><sup>)</sup> found a reduction in peripheral airway resistance and consequently
in total resistance of the respiratory system after a single session with Flutter valve in
hypersecretive patients with bronchiectasis. Similarly, but using body plethysmography, we
found an improvement in Raw and SGVa after both ELTGOL and FLUTTER in patients with cystic
fibrosis. When comparing these techniques, ELTGOL has proven superiority in improving the
overall airway permeability (Raw and SGVa), but in the within-intervention analysis, only
FLUTTER reduced pulmonary hyperinflation and air trapping. Despite this outcome, confidence
interval analysis showed no differences when comparing TLC, RV, RV/TLC, and FRC between the
two interventions. As, in theory, the airway impedance influences these static volumes, it
is likely that a larger sample size would enable us to observe significant differences also
in the within-intervention analysis for ELTGOL, corroborating the other clinical (sputum
production) and physiological (airway resistance and conductance) findings.</p><p>Because conventional physiotherapy, i.e., postural drainage associated with chest
percussion and/or vibration, cannot be carried out without a therapist, novel airway
clearance techniques have been proposed with the aim of improving cystic fibrosis patients&#x02019;
adherence to treatment. The Flutter valve is easy to use and has well-proven clinical
benefits<xref rid="r17" ref-type="bibr">17</xref><sup>)</sup>, making this oscillatory
device a common choice for the treatment of cystic fibrosis patients. In our study, ELTGOL
was equivalent to the Flutter valve in the reduction of airway resistance and pulmonary
hyperinflation, showing superiority for secretion removal. The underlying mechanism of
ELTGOL uses airways compression to improve air-liquid interaction in the peripheral airways,
thus promoting pulmonary secretion displacement. This principle also supports the use of
autogenic drainage, in which the patient has to breathe at different pulmonary volumes to
&#x0201c;unstick,&#x0201d; &#x0201c;collect,&#x0201d; and &#x0201c;evacuate&#x0201d; the secretions from the peripheral airways<xref rid="r18" ref-type="bibr">18</xref><sup>)</sup>. Like Flutter valve, autogenic drainage
has proven efficacy for patients with cystic fibrosis, but ELTGOL is inexpensive and easier
to perform. These advantages have raised interest among therapists and researchers in the
last few years. Therefore, ELTGOL has been shown to have positive effects in chronic
obstructive pulmonary disease<xref rid="r19" ref-type="bibr">19</xref><sup>)</sup> and
chronic bronchitis<xref rid="r20" ref-type="bibr">20</xref><sup>)</sup> exacerbations and in
stable patients with bronchiectasis<xref rid="r21" ref-type="bibr">21</xref><sup>)</sup> and
chronic bronchitis<xref rid="r22" ref-type="bibr">22</xref><sup>)</sup>. Among these studies
the only study on the long-term impact of ELTGOL did not show any proven efficacy in
reducing hospitalization or the number of exacerbations<xref rid="r19" ref-type="bibr">19</xref><sup>)</sup>.</p><p>The main limitations of the present study are the small sample size and the lack of
evaluation of the long-term effects of the interventions. Nevertheless, because the
literature lacks information on the impact of ELTGOL in adult cystic fibrosis patients, in
this first study, we evaluated only the short-term effects of the technique, comparing its
results with a well-established procedure. Therefore, our results are not enough to
recommend ELTGOL as a routine procedure in the treatment of CF patients but point out that
is worthwhile to perform further research on this technique using long-term treatment
designs and clinically relevant outcomes, such as quality of life and incidence of pulmonary
exacerbations.</p><p>In conclusion, ELTGOL promoted higher secretion removal and improvement in airway
resistance and conductance than the Flutter valve. These techniques were equivalent in
reducing pulmonary hyperinflation and air trapping in adult cystic fibrosis patients.</p></sec></body><back><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><mixed-citation publication-type="journal"><person-group><name><surname>Ashlock</surname><given-names>MA</given-names></name><name><surname>Olson</surname><given-names>ER</given-names></name></person-group>: <article-title>Therapeutics development for cystic fibrosis: a successful
model for a multisystem genetic disease</article-title>. <source>Annu Rev Med</source>,
<year>2011</year>, <volume>62</volume>: <fpage>107</fpage>&#x02013;<lpage>125</lpage>
<pub-id pub-id-type="pmid">21226613</pub-id></mixed-citation></ref><ref id="r2"><label>2</label><mixed-citation publication-type="journal"><person-group><name><surname>Davis</surname><given-names>PB</given-names></name></person-group>: <article-title>Cystic fibrosis since 1938</article-title>. <source>Am J
Respir Crit Care Med</source>, <year>2006</year>, <volume>173</volume>:
<fpage>475</fpage>&#x02013;<lpage>482</lpage>
<pub-id pub-id-type="pmid">16126935</pub-id></mixed-citation></ref><ref id="r3"><label>3</label><mixed-citation publication-type="journal"><person-group><name><surname>Bucks</surname><given-names>RS</given-names></name><name><surname>Hawkins</surname><given-names>K</given-names></name><name><surname>Skinner</surname><given-names>TC</given-names></name><etal>et al.</etal></person-group>: <article-title>Adherence to treatment in adolescents with cystic
fibrosis: the role of illness perceptions and treatment beliefs</article-title>.
<source>J Pediatr Psychol</source>, <year>2009</year>, <volume>34</volume>:
<fpage>893</fpage>&#x02013;<lpage>902</lpage>
<pub-id pub-id-type="pmid">19196850</pub-id></mixed-citation></ref><ref id="r4"><label>4</label><mixed-citation publication-type="journal"><person-group><name><surname>Pisi</surname><given-names>G</given-names></name><name><surname>Chetta</surname><given-names>A</given-names></name></person-group>: <article-title>Airway clearance therapy in cystic fibrosis
patients</article-title>. <source>Acta Biomed</source>, <year>2009</year>,
<volume>80</volume>: <fpage>102</fpage>&#x02013;<lpage>106</lpage>
<pub-id pub-id-type="pmid">19848046</pub-id></mixed-citation></ref><ref id="r5"><label>5</label><mixed-citation publication-type="journal"><person-group><name><surname>Cohen-Cymberknoh</surname><given-names>M</given-names></name><name><surname>Shoseyov</surname><given-names>D</given-names></name><name><surname>Kerem</surname><given-names>E</given-names></name></person-group>: <article-title>Managing cystic fibrosis: strategies that increase life
expectancy and improve quality of life</article-title>. <source>Am J Respir Crit Care
Med</source>, <year>2011</year>, <volume>183</volume>:
<fpage>1463</fpage>&#x02013;<lpage>1471</lpage>
<pub-id pub-id-type="pmid">21330455</pub-id></mixed-citation></ref><ref id="r6"><label>6</label><mixed-citation publication-type="journal"><person-group><name><surname>Sontag</surname><given-names>MK</given-names></name><name><surname>Quittner</surname><given-names>AL</given-names></name><name><surname>Modi</surname><given-names>AC</given-names></name><etal>et al.</etal></person-group>: Investigators and Coordinators of the Airway Secretion Clearance Trial:
<article-title>Lessons learned from a randomized trial of airway secretion clearance
techniques in cystic fibrosis</article-title>. <source>Pediatr Pulmonol</source>,
<year>2010</year>, <volume>45</volume>: <fpage>291</fpage>&#x02013;<lpage>300</lpage>
<pub-id pub-id-type="pmid">20146387</pub-id></mixed-citation></ref><ref id="r7"><label>7</label><mixed-citation publication-type="journal"><person-group><name><surname>Postiaux</surname><given-names>G</given-names></name><name><surname>Lahaye</surname><given-names>JM</given-names></name><name><surname>Lens</surname><given-names>E</given-names></name><etal>et al.</etal></person-group>: <article-title>Le drainage postural en question</article-title>.
<source>Kinesith Sci</source>, <year>1985</year>, <volume>238</volume>:
<fpage>13</fpage>&#x02013;<lpage>43</lpage></mixed-citation></ref><ref id="r8"><label>8</label><mixed-citation publication-type="journal"><person-group><name><surname>Postiaux</surname><given-names>G</given-names></name><name><surname>Lens</surname><given-names>E</given-names></name></person-group>: <article-title>Orientations des choix th&#x000e9;rapeutiques en kin&#x000e9;sith&#x000e9;rapie
respiratoire</article-title>. <source>Rev Mains Libres</source>, <year>1987</year>,
<volume>11</volume>: <fpage>9</fpage>&#x02013;<lpage>13</lpage></mixed-citation></ref><ref id="r9"><label>9</label><mixed-citation publication-type="journal"><person-group><name><surname>Konstan</surname><given-names>MW</given-names></name><name><surname>Stern</surname><given-names>RC</given-names></name><name><surname>Doershuk</surname><given-names>CF</given-names></name></person-group>: <article-title>Efficacy of the Flutter device for airway mucus clearance
in patients with cystic fibrosis</article-title>. <source>J Pediatr</source>,
<year>1994</year>, <volume>124</volume>: <fpage>689</fpage>&#x02013;<lpage>693</lpage>
<pub-id pub-id-type="pmid">8176554</pub-id></mixed-citation></ref><ref id="r10"><label>10</label><mixed-citation publication-type="journal"><person-group><name><surname>Fink</surname><given-names>JB</given-names></name><name><surname>Mahlmeister</surname><given-names>MJ</given-names></name></person-group>: <article-title>High-frequency oscillation of the airway and chest
wall</article-title>. <source>Respir Care</source>, <year>2002</year>,
<volume>47</volume>: <fpage>797</fpage>&#x02013;<lpage>807</lpage>
<pub-id pub-id-type="pmid">12088550</pub-id></mixed-citation></ref><ref id="r11"><label>11</label><mixed-citation publication-type="journal"><person-group><name><surname>Placidi</surname><given-names>G</given-names></name><name><surname>Cornacchia</surname><given-names>M</given-names></name><name><surname>Polese</surname><given-names>G</given-names></name><etal>et al.</etal></person-group>: <article-title>Chest physiotherapy with positive airway pressure: a pilot
study of short-term effects on sputum clearance in patients with cystic fibrosis and
severe airway obstruction</article-title>. <source>Respir Care</source>,
<year>2006</year>, <volume>51</volume>: <fpage>1145</fpage>&#x02013;<lpage>1153</lpage>
<pub-id pub-id-type="pmid">17005060</pub-id></mixed-citation></ref><ref id="r12"><label>12</label><mixed-citation publication-type="journal">American Thoracic Society:
<article-title>1994 Update</article-title>. <source>Am J Respir Crit Care Med</source>,
<year>1995</year>, <volume>152</volume>: <fpage>1107</fpage>&#x02013;<lpage>1136</lpage>
<pub-id pub-id-type="pmid">7663792</pub-id></mixed-citation></ref><ref id="r13"><label>13</label><mixed-citation publication-type="journal"><person-group><name><surname>Pereira</surname><given-names>CA</given-names></name><name><surname>Sato</surname><given-names>T</given-names></name><name><surname>Rodrigues</surname><given-names>SC</given-names></name></person-group>: <article-title>New reference values for forced spirometry in white adults
in Brazil</article-title>. <source>J Bras Pneumol</source>, <year>2007</year>,
<volume>33</volume>: <fpage>397</fpage>&#x02013;<lpage>406</lpage>
<pub-id pub-id-type="pmid">17982531</pub-id></mixed-citation></ref><ref id="r14"><label>14</label><mixed-citation publication-type="journal"><person-group><name><surname>Neder</surname><given-names>JA</given-names></name><name><surname>Andreoni</surname><given-names>S</given-names></name><name><surname>Castelo-Filho</surname><given-names>A</given-names></name><etal>et al.</etal></person-group>: <article-title>Reference values for lung function tests. I. Static
volumes</article-title>. <source>Braz J Med Biol Res</source>, <year>1999</year>,
<volume>32</volume>: <fpage>703</fpage>&#x02013;<lpage>717</lpage>
<pub-id pub-id-type="pmid">10412549</pub-id></mixed-citation></ref><ref id="r15"><label>15</label><mixed-citation publication-type="journal"><person-group><name><surname>van der Schans</surname><given-names>CP</given-names></name></person-group>: <article-title>Airway clearance: assessment of
techniques</article-title>. <source>Paediatr Respir Rev</source>, <year>2002</year>,
<volume>3</volume>: <fpage>110</fpage>&#x02013;<lpage>114</lpage>
<pub-id pub-id-type="pmid">12297056</pub-id></mixed-citation></ref><ref id="r16"><label>16</label><mixed-citation publication-type="journal"><person-group><name><surname>Figueiredo</surname><given-names>PH</given-names></name><name><surname>Zin</surname><given-names>WA</given-names></name><name><surname>Guimar&#x000e3;es</surname><given-names>FS</given-names></name></person-group>: <article-title>Flutter valve improves respiratory mechanics and sputum
production in patients with bronchiectasis</article-title>. <source>Physiother Res
Int</source>, <year>2012</year>, <volume>17</volume>:
<fpage>12</fpage>&#x02013;<lpage>20</lpage>
<pub-id pub-id-type="pmid">21182171</pub-id></mixed-citation></ref><ref id="r17"><label>17</label><mixed-citation publication-type="journal"><person-group><name><surname>Morrison</surname><given-names>L</given-names></name><name><surname>Agnew</surname><given-names>J</given-names></name></person-group>: <article-title>Oscillating devices for airway clearance in people with
cystic fibrosis</article-title>. <source>Cochrane Database Syst Rev</source>,
<year>2009</year>, <volume>21</volume>: <fpage>CD006842</fpage>
<pub-id pub-id-type="pmid">19160305</pub-id></mixed-citation></ref><ref id="r18"><label>18</label><mixed-citation publication-type="journal"><person-group><name><surname>Sch&#x000f6;ni</surname><given-names>MH</given-names></name></person-group>: <article-title>Autogenic drainage: a modern approach to physiotherapy in
cystic fibrosis</article-title>. <source>J R Soc Med</source>, <year>1989</year>,
<volume>82</volume>: <fpage>32</fpage>&#x02013;<lpage>37</lpage>
<pub-id pub-id-type="pmid">2657053</pub-id></mixed-citation></ref><ref id="r19"><label>19</label><mixed-citation publication-type="journal"><person-group><name><surname>Kodric</surname><given-names>M</given-names></name><name><surname>Garuti</surname><given-names>G</given-names></name><name><surname>Colomban</surname><given-names>M</given-names></name><etal>et al.</etal></person-group>: <article-title>The effectiveness of a bronchial drainage technique
(ELTGOL) in COPD exacerbations</article-title>. <source>Respirology</source>,
<year>2009</year>, <volume>14</volume>: <fpage>424</fpage>&#x02013;<lpage>428</lpage>
<pub-id pub-id-type="pmid">19192230</pub-id></mixed-citation></ref><ref id="r20"><label>20</label><mixed-citation publication-type="journal"><person-group><name><surname>Bellone</surname><given-names>A</given-names></name><name><surname>Lascioli</surname><given-names>R</given-names></name><name><surname>Raschi</surname><given-names>S</given-names></name><etal>et al.</etal></person-group>: <article-title>Chest physical therapy in patients with acute exacerbation
of chronic bronchitis: effectiveness of three methods</article-title>. <source>Arch Phys
Med Rehabil</source>, <year>2000</year>, <volume>81</volume>:
<fpage>558</fpage>&#x02013;<lpage>560</lpage>
<pub-id pub-id-type="pmid">10807091</pub-id></mixed-citation></ref><ref id="r21"><label>21</label><mixed-citation publication-type="journal"><person-group><name><surname>Guimar&#x000e3;es</surname><given-names>FS</given-names></name><name><surname>Mo&#x000e7;o</surname><given-names>VJ</given-names></name><name><surname>Menezes</surname><given-names>SL</given-names></name><etal>et al.</etal></person-group>: <article-title>Effects of ELTGOL and Flutter VRP1<sup>&#x000ae;</sup> on the dynamic and
static pulmonary volumes and on the secretion clearance of patients with
bronchiectasis</article-title>. <source>Rev Bras Fisioter</source>, <year>2012</year>,
<volume>16</volume>: <fpage>108</fpage>&#x02013;<lpage>113</lpage>
<pub-id pub-id-type="pmid">22481696</pub-id></mixed-citation></ref><ref id="r22"><label>22</label><mixed-citation publication-type="journal"><person-group><name><surname>Martins</surname><given-names>JA</given-names></name><name><surname>Dornelas de Andrade</surname><given-names>A</given-names></name><name><surname>Britto</surname><given-names>RR</given-names></name><etal>et al.</etal></person-group>: <article-title>Effect of slow expiration with glottis opened in lateral
posture (ELTGOL) on mucus clearance in stable patients with chronic
bronchitis</article-title>. <source>Respir Care</source>, <year>2012</year>,
<volume>57</volume>: <fpage>420</fpage>&#x02013;<lpage>426</lpage>
<pub-id pub-id-type="pmid">22005107</pub-id></mixed-citation></ref></ref-list></back></article>